In March 2019, I made my first visit to Harvard Medical School—one of those pivotal moments you don’t forget. I was there to meet with two of the most respected minds in longevity and genetics: Dr. George Church and Dr. David Sinclair. My goal was simple but ambitious—I wanted to hear from them directly whether my idea of targeting all biological hallmarks of aging simultaneously using natural, over-the-counter ingredients had real scientific merit.
I came in fully prepared to be challenged—or even dismissed outright. Instead, I left feeling inspired and validated. Both Dr. Church and Dr. Sinclair were optimistic, supportive, and encouraging. It was during those conversations, alongside other ongoing discussions with experts in the field, that I made the decision to launch NOVOS.
That moment at Harvard marked the beginning of a journey that would go on to redefine what a consumer longevity company could be. Dr. George Church didn’t just encourage me—he generously agreed to join our Scientific Advisory Board. He played an integral role in shaping the initial formulation of NOVOS Core and has been a trusted advisor on our scientific study designs and research strategy ever since.
Six years later, I returned to his lab at Harvard. Although we had been regularly in touch since our first meeting, this was the first time I had been back since that game-changing visit. This time, I wasn’t just there as a hopeful entrepreneur with an idea—I came back with a company that had built the most promising and scientifically validated longevity supplement and earned the trust of customers around the globe, who had consumed more than 10 million servings of our formula to date.
The visit was more than symbolic—it was deeply meaningful. I had the honor of interviewing Dr. Church for my upcoming YouTube channel, Slow My Age, where we discussed the future of longevity science, the power of genetics and epigenetics, and how we might someday rejuvenate even the hardest-to-reach organs like the heart and brain. We also explored the philosophical and ethical implications of radically extending the human lifespan.
Dr. Church’s brilliance and generosity never cease to amaze me. His work has touched the lives of hundreds of millions—arguably billions—by making genetic sequencing more affordable and accessible. His innovations reduced the cost of sequencing by over 20 million times, opening the doors to a genomic revolution. His research was foundational for the creation of CRISPR gene editing. And his work with de-extinction, synthetic biology, and bioethics are at the top of the field.
NOVOS would not be where it is today without the guidance, insights, and belief of mentors like Dr. Church. And while we’ve already accomplished a great deal, this visit reminded me that we’re still just getting started.
We’re building something at NOVOS that’s never existed before—a scientifically validated path to slower aging, greater healthspan, and longer life—that is directly accessible by the consumer. And we’re doing it with the support of world-renowned researchers, peer-reviewed studies, and a passionate community that believes in evidence, not hype.
I’m more energized than ever to continue pushing boundaries, conducting rigorous research, and sharing everything we learn with you. Because the future of longevity isn’t just coming—it’s already underway.